APP and Alzheimer disease: Importantly, we developed two agomirs, which were shown to upregulate CPE expression, promote adult hippocampal neurogenesis, improve newborn neuron dendritic development, rescue memory deficits and confer neuroprotection against various pathologies of AD in the hippocampal neurogenic niche of middle-aged APP/PS1 transgenic mice, thus showing great therapeutic potential to counteract AD.